Furthermore, the possibility of targeting therapeutic treatments to the NKG2D pathway in human inflammatory diseases was confirmed by administering a single injection of α-NKG2D neutralizing antibody to patients with Crohn’s disease, which reduced disease activity (Allez et al., 2017). This evidence concerns the gene KLRK1 and Crohn disease.